WASHINGTON, D.C., United States – May 8, 2026
The U.S. Food and Drug Administration announced the release of a final industry guidance titled “Postapproval Pregnancy Safety Studies”, providing updated recommendations for how pharmaceutical and biotechnology companies should collect and evaluate safety data for drugs and biologics used during pregnancy. The guidance is intended to improve the quality and consistency of postmarketing pregnancy safety research and help generate clearer clinical information for healthcare providers and pregnant patients making treatment decisions. According to the FDA, many approved therapies currently lack sufficient human pregnancy safety data at the time of approval because pregnant women are often excluded from clinical trials.
As a result, physicians frequently prescribe medications during pregnancy without robust evidence regarding potential maternal, fetal, or developmental risks. The newly released guidance outlines multiple scientific approaches sponsors can use after approval to better assess medication safety during pregnancy, including pregnancy registries, observational studies, real-world evidence analysis, pharmacovigilance programs, and descriptive case-report studies. The agency stated that improving postapproval pregnancy data collection could significantly strengthen drug labeling information and support more informed risk-benefit assessments in clinical practice.
FDA Pushes for Stronger Real-World Pregnancy Safety Evidence
The FDA emphasized that postmarketing pregnancy safety evaluation remains critically important because many chronic and acute medical conditions require ongoing treatment during pregnancy, including autoimmune diseases, diabetes, cardiovascular disorders, infections, neurological conditions, and mental health illnesses. However, limited pregnancy-specific clinical trial participation has historically created major evidence gaps surrounding medication safety for both pregnant patients and developing fetuses. FDA Commissioner Marty Makary stated that pregnant women and healthcare providers need more reliable information to support informed treatment decisions and reduce uncertainty surrounding therapeutic use during pregnancy.
The guidance encourages drug developers to incorporate multiple complementary data sources capable of identifying safety signals more rapidly and accurately. These include long-term pregnancy exposure registries, retrospective healthcare database analyses, electronic health record studies, and real-world observational research capable of tracking maternal outcomes, fetal development, congenital abnormalities, birth complications, and neonatal health outcomes. The FDA noted that many pregnancy safety studies are non-randomized by necessity, making strong epidemiologic methodologies and statistical rigor especially important for generating meaningful evidence.
Advertisement
New Guidance Supports Improved Drug Labeling and Risk Communication
According to the FDA, the ultimate objective of these postapproval pregnancy studies is to improve drug labeling and ensure healthcare professionals have access to more clinically relevant safety information when counseling pregnant patients. The agency stated that pregnancy-related safety signals are often difficult to identify due to small patient populations, varying disease severity, ethical limitations surrounding randomized studies, and incomplete reporting of adverse events. The guidance therefore recommends collaboration with multidisciplinary experts in obstetrics, pediatrics, genetics, epidemiology, pharmacovigilance, and biostatistics to improve study quality and interpretation of pregnancy-related outcomes.
Tracy Beth Hoeg, Acting Director of the FDA’s Center for Drug Evaluation and Research (CDER), noted that many therapies are already being prescribed during pregnancy despite insufficient pregnancy-specific evidence from preapproval clinical trials. She stated that the new guidance provides practical recommendations for leveraging postmarketing data sources and improving study design so that pregnancy-related risks can be identified earlier and communicated more effectively to clinicians and the public. The agency also clarified that FDA guidance documents reflect current regulatory thinking and scientific recommendations but do not establish legally enforceable requirements.
Pregnancy Safety Research Gains Importance Across Pharma and Biotech
The updated FDA guidance reflects growing regulatory and industry focus on improving inclusion, monitoring, and evidence generation for historically underrepresented patient populations, particularly pregnant women. As precision medicine, biologics, gene therapies, and targeted therapeutics continue expanding across healthcare, regulators are increasingly emphasizing the importance of understanding how these products affect pregnancy outcomes and fetal development. The pharmaceutical industry has faced longstanding criticism for the lack of robust pregnancy data accompanying many newly approved therapies, especially in areas such as oncology, immunology, rare diseases, infectious diseases, and neurology.
Advances in real-world evidence infrastructure, electronic medical records, healthcare databases, and postmarketing surveillance technologies are now enabling more sophisticated pregnancy safety evaluations than previously possible. The FDA’s latest recommendations may encourage broader adoption of integrated pregnancy surveillance programs capable of improving maternal-fetal safety assessment while strengthening clinician confidence in prescribing decisions. The guidance also aligns with wider global regulatory efforts focused on enhancing pharmacovigilance standards and improving transparency surrounding medication use during pregnancy.
Source: FDA press release
